Welcome to our dedicated page for abrdn Life Sciences Investors news (Ticker: HQL), a resource for investors and traders seeking the latest updates and insights on abrdn Life Sciences Investors stock.
abrdn Life Sciences Investors (NYSE: HQL) provides focused exposure to innovative companies in biotechnology, pharmaceuticals, and healthcare technologies. This news hub delivers official updates and analysis for stakeholders tracking this specialized closed-end fund.
Access timely announcements including earnings reports, portfolio changes, and strategic initiatives directly from the fund and verified sources. Our curated collection helps investors monitor HQL's performance in dynamic life sciences markets while understanding sector-specific developments that may impact valuation.
Key updates cover management insights, regulatory milestones, and investment strategy adjustments. Regular updates ensure you stay informed about the fund's positioning within evolving healthcare innovation trends. Bookmark this page for efficient tracking of HQL's market activities and fundamental developments.
On February 15, 2022,
On November 12, 2021, Tekla Life Sciences Investors (HQL) announced a distribution of $0.42 per share. The record date is November 24, 2021, with a payable date of December 31, 2021. Shares will trade ex-distribution on November 23, 2021. The distribution will be paid in newly issued shares unless a cash option is elected by shareholders. Shareholders must respond to their brokers to choose cash or are required to notify Computershare Investor Services by December 21, 2021.
On August 17, 2021, Tekla Life Sciences Investors announced a distribution of $0.43 per share, with a record date of August 27, 2021 and a payable date of September 30, 2021. The stock will trade ex-distribution on August 26, 2021. The distribution will be in newly issued shares unless shareholders opt for cash. Shares will be valued at the lower of net asset value or market price on September 22, 2021. Shareholders can request cash payment via their brokers or Computershare Investor Services before September 21, 2021.
On May 18, 2021, Tekla Life Sciences Investors announced a $0.41 per share stock distribution, with a record date of May 28, 2021 and a payable date of June 30, 2021. The fund will trade ex-distribution on May 27, 2021. Shareholders will receive newly issued shares based on the lower of net asset value or market price as of June 22, 2021. Cash payment options are available, with notifications due by June 21, 2021. Tekla Life Sciences Investors (NYSE: HQL) focuses on investments in life sciences companies.
Tekla Life Sciences Investors announced a renewal of its share repurchase program, allowing the purchase of up to 12% of outstanding common shares until July 14, 2022. This decision aims to enhance shareholder value and reduce the discount between market price and net asset value. The timing and amount of repurchases will be at the discretion of Tekla Capital Management LLC, with no guarantee of specific purchase levels or market price increase. The Fund focuses on investments in the life sciences sector, listed under NYSE symbol HQL.
On February 16, 2021, Tekla Life Sciences Investors announced a distribution of $0.43 per share, with a record date set for February 26, 2021 and payable on March 31, 2021. The fund will trade ex-distribution on February 25, 2021. Shareholders will automatically receive newly issued shares valued at either the net asset value or market price on March 23, 2021. Options for cash payments are available for shareholders with instructions to request payment through their brokers or via Computershare Investor Services.
On January 6, 2021, Tekla Life Sciences Investors distributed $0.02 per share, linked to net realized long-term capital gains. The total net unrealized appreciation and realized gains on portfolio securities stand at $166.96 million. The fund's cumulative distributions for the fiscal year thus far is $0.42 per share, with 93% from short-term capital gains. The average annual return at NAV from Nov 30, 2015, to Nov 30, 2020, is 6.17%. Tekla Capital Management, managing around $3.3 billion in assets, advises this closed-end fund. For inquiries, contact Destra Capital Advisors.
On December 21, 2020, Tekla Life Sciences Investors announced a special cash distribution of $0.02 per share to meet annual tax distribution requirements. The record date for this distribution is December 31, 2020, and the payable date is January 6, 2021. The fund will trade ex-distribution on December 30, 2020. This payment will be in cash and will be taxable to shareholders for the year 2020. Tekla Life Sciences Investors (NYSE: HQL) invests in public and private life sciences companies.
On November 16, 2020, Tekla Life Sciences Investors (NYSE: HQL) announced a distribution of $0.40 per share, with a record date of November 27, 2020 and a payable date of December 31, 2020. The shares will be issued unless shareholders request cash payment by December 21, 2020. The share valuation will be at the lower of net asset value or market price on December 22, 2020. This closed-end fund invests in life sciences companies, advised by Tekla Capital Management LLC.
On September 30, 2020, Tekla Life Sciences Investors announced a distribution of $0.41 per share, primarily sourced from net realized long-term capital gains. The fund's total net assets under management are approximately $3.1 billion. As of July 31, 2020, the average annual return at NAV was 2.16%, with a cumulative total return of 32.41% for the fiscal year. The current distribution's annualized rate is 8.01% of NAV. The fund's performance is subject to changes based on future realized gains and losses.
FAQ
What is the current stock price of abrdn Life Sciences Investors (HQL)?
What is the market cap of abrdn Life Sciences Investors (HQL)?
